BioLogics Selected By Tesaro As A Specialty Pharmacy Provider For ZEJULATM (Niraparib), Approved For The Treatment Of Recurrent Ovarian Cancer

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by TESARO, Inc. to be a specialty pharmacy provider in the distribution network for ZEJULA^TM (niraparib).

“This is a very exciting advancement for the treatment of this patient population, and we are thrilled to be part of the distribution network”

Approved by the U.S. Food and Drug Administration (FDA) on March 27, 2017, ZEJULA is a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

The American Cancer Society estimates that over 22,000 women will be diagnosed with ovarian cancer in 2017. Historically, there have been few treatment options for women with recurrent ovarian cancer.

“This is a very exciting advancement for the treatment of this patient population, and we are thrilled to be part of the distribution network,” said Brandon Tom, vice president, Biopharma Services, McKesson Specialty Health.

Clinical trial results demonstrated that treatment with ZEJULA reduced the risk of disease progression or death by 74% in patients with germline BRCA (BReast CAncer susceptibility gene) mutations (HR 0.26) and by 55% in patients without germline BRCA mutations (HR 0.45).

Biologics’ oncology specialty pharmacy is supported by a multidisciplinary care team that includes a pharmacist, oncology nurse and financial counselor. Individualized care plans are developed to address the unique clinical, financial and emotional needs of each patient and to streamline communication back to the treating provider.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

Select Important Safety Information

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) was reported in patients treated with ZEJULA in all clinical studies. Discontinue ZEJULA if MDS/AML is confirmed.

Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia) have been reported in patients treated with ZEJULA. Do not start ZEJULA until patients have recovered from hematological toxicity caused by previous chemotherapy (= Grade 1). Monitor complete blood counts weekly for the first month, monthly for the next 11 months of treatment, and periodically after this time.

Hypertension and hypertensive crisis have been reported in patients treated with ZEJULA. Monitor blood pressure and heart rate monthly for the first year and periodically thereafter during treatment with ZEJULA. Closely monitor patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Based on its mechanism of action, ZEJULA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for six months after receiving the final dose. Because of the potential for serious adverse reactions in breastfed infants from ZEJULA, advise a lactating woman not to breastfeed during treatment with ZEJULA and for one month after receiving the final dose.

In clinical studies, the most common adverse reactions included: thrombocytopenia, anemia, neutropenia, nausea, constipation, vomiting, abdominal pain/distension, mucositis/stomatitis, diarrhea, fatigue/asthenia, decreased appetite, headache, insomnia, nasopharyngitis, dyspnea, rash and hypertension.

Please see full Prescribing Information for additional Safety Information, available at www.zejula.com.

About Biologics

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.

Biologics is part of McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.